- Published: April 2012
Drug-eluting Stent Market in Europe 2011-2015
- Published: April 2012
- 36 pages
- Infiniti Research Limited
TechNavio’s analysts forecast the Drug-eluting Stent market in Europe to grow at a CAGR of 4.3 percent over the period 2011–2015. One of the key factors contributing to this market growth is the high prevalence of cardiovascular diseases in the region. The Drug-eluting Stent market in Europe has also been witnessing the trend of formation of strategic alliances among vendors. However, the decline in the average price of drug-eluting stent could pose a challenge to the growth of this market.
TechNavio’s report, the Drug-eluting Stent Market in Europe 2011–2015, has been prepared based on an in-depth analysis of the market with inputs from industry experts. The report focuses on Europe; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this market space include Boston Scientific Corp., Abbott Vascular, Medtronic Inc., and Cordis Corp.
Key questions answered in this report:
What will the market size be in 2015 and at what rate will it grow?
What key trends is this market subject to?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the opportunities and threats faced by each of these key vendors?
What are the strengths and weaknesses of each of these key vendors?
SHOW LESS READ MORE >
01. Executive Summary
03. Market Coverage
04. Market Landscape
05. Rate of Incidence and Prevalence
06. Vendor Landscape
07. Buying Criteria
08. Market Growth Drivers
09. Drivers and their Impact
10. Market Challenges
11. Impact of Drivers and Challenges
12. Market Trends
13. Key Vendor Analysis
13.1 Boston Scientific Corp.
13.2 Abbott Vascular
13.3 Medtronic Inc.
13.4 Cordis Corp.
14. Other Reports in this Series
List of Exhibits:
Exhibit 1: Drug-eluting Stent Market in Europe 2011–2015 (US$ billion)
Exhibit 2: Drug-eluting Stent Market in Europe 2011–2015 (thousand units)
Exhibit 3: Average Selling Price of Drug-eluting Stent in Europe 2011–2015 (US$)
Exhibit 4: Coronary Stent Market in Europe by Product Segmentation 2011–2015
Exhibit 5: Drug-eluting Stent Market in Europe by Vendor Segmentation 2011
TechNavio Announces the Publication of its Report – Drug-eluting Stent Market in Europe 2011–2015
TechNavio today launched its Drug-eluting Stent Market in Europe 2011–2015 report based on an in-depth study focusing exclusively on Europe. The report aims to aid decision makers’ understanding of the present and future landscape of the market.
Commenting on the report, an analyst from TechNavio’s Healthcare team said; “Drug-eluting Stent (DES) vendors are opting for strategic alliances as a means of sharing their core competencies to develop innovative products and also to avoid litigation issues. Recently, two leading vendors in the DES market in Europe, Boston Scientific and Abbott Vascular, entered into one such agreement.”
According to the report, the prevalence of cardiovascular disease (CVDs) is increasing rapidly in Europe. Over the past decade, as a result of unhealthy dietary habits and lack of physical activity due to hectic lifestyles, there has been an increase in the incidence of diseases such as hypercholesterolemia, coronary heart disease (CHD), and diabetes. This has led to an increase in the demand for catheter-based treatment of heart diseases. Furthermore, the rapidly expanding, aging population is resulting in an increase in the number of people prone to CVD. DES treatment is considered to be more sustainable than treatment using bare-metal stents (BMSs) for the treatment of CHD. Hence, a large number of cardiologists in Europe recommend the use of DESs to patients suffering from CHD to ensure that they receive a good-quality cure. Thus, the increasing number of patients suffering from CVD increases the demand for DESs, and this is expected to help the DES market in Europe expand significantly by 2015.
Further, the report also discusses that the steady decline in the average selling price of DESs has the highest negative impact on the DES market in Europe.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key players.
|Electronic (PDF)||The report will be emailed to you. The report is sent in PDF format.||This is a single user license, allowing one specific user access to the product.|
|1 - 5 Users||The report will be emailed to you. The report is sent in PDF format.||This is a 1-5 user licence, allowing up to five users have access to the product.|
|Enterprisewide||The report will be emailed to you. The report is sent in PDF format.||This is an enterprise license, allowing all employees within your organisation access to the product.|